Enregistrement :
31
de
67
(2017-02-13
à
2017-07-27)
Politique ou Programme
Canada’s Access to Medicines Regime (CAMR), certified under the Patent Act, which allows developing countries to access drugs at a lower cost, with regard to ensuring that Intellectual Property rights and anti-diversion mechanisms continue to be respected.
National Immunization Strategy.
Advocacy to seek continued investment in vaccines funding and an overall strategy for prevention of disease in Canada.
PWGSC Integrity Framework - Clarifying the process for procurement of vaccines and possibly pharmaceuticals under the evolving procurement framework.
Patented Medicines Review Board (PMPRB), certified under the Patent Act and whose guidelines seek to ensure a balance between the prices set by manufacturers for patented medicines sold in Canada and the maintenance of an attractive environment for pharmaceutical research and development. Specifically with regard to ensuring that any actions and proposed changes by the PMPRB are consistent with the mandate assigned by Parliament.
Science and Technology (S&T) Strategy: Mobilizing Science and Technology to Canada's Advantage.
Advocacy for measures which will allow for commercialization in health care to occur and for Canada to remain competitive internationally on Intellectual Property and other fronts.
The Common Drug Review (CDR) process for reviewing new drugs and providing listing recommendations to publicly funded drug benefit plans in Canada.
Ensuring the access needs of Canadian patients are met by advocating on activities undertaken in the context of the CDR.
The National Pharmaceutical Strategy (NPS) as agreed by First Ministers in 2004.
Advocacy for ways to increase access to medicines and vaccines for Canadian patients.
Politique ou Programme, Proposition législative, Projet de loi ou résolution, Règlement
Canada-European Union Comprehensive Economic Trade Agreement with respect to strengthening Intellectual Property Protection provisions under the Patent Act and related regulations.
Politique ou Programme, Subvention, Contribution ou autre avantage financier
FedDev Ontario Advanced Manufacturing Fund - advancing manufacturing of innovative pharmaceutical products in southern Ontario
Proposition législative, Projet de loi ou résolution
Bill C17 Protecting Canadians from Unsafe Drugs Act - improving adverse event reporting, improve transparency of clinical trials and improve consistency of product labelling
Food and Drugs Act and the bill formerly known as Bill C-51: An Act to amend the Food and Drugs Act and to make consequential amendments to other Acts. Specifically, with respect to the renewal of the drug approval process.
Advocacy to ensure that Canada's review and approval process is timely, safe, effective, competitive and consistent with other jurisdictions.
Proposition législative, Projet de loi ou résolution, Règlement
Canada-Europe Comprehensive Economic and Trade Agreement - Intellectual Property Provisions
Règlement
Patented Medicines (Notice of Compliance) Regulations which seek to balance the protection of Intellectual Property (IP) and patents with cost containment.
Advocacy to ensure that IP rights are respected and internationally competitive in order to promote Research and Development.